

Image



Image



This page is intended for UK healthcare professionals only.

FABHALTA® is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.<sup>1</sup>

## **FABHALTA®▼ (iptacopan) Connected - Stronger Together**

**Helping your eligible patients prescribed FABHALTA® start and stay**

## **on track with their treatment**

Connected – Stronger Together is a patient support programme developed and funded by Novartis Pharmaceuticals UK Ltd.

It provides support to patients prescribed iptacopan to help them better understand and manage their paroxysmal nocturnal haemoglobinuria (PNH) and treatment.

Connected – Stronger Together, designed with the help of patients, provides information, resources, and support that specifically address the unique needs of your patients as they start their treatment with iptacopan and throughout their treatment journey.


The Connected – Stronger Together patient support programme can help patients:

- Receive personalised support based on their specific challenges
- Understand and manage possible side effects associated with their treatment
- Learn more about their treatment
- Access information about treatment tracking and monitoring
- Learn more about PNH
- Find information and sources of emotional and well-being support

---

## **Two simple ways for your patients to enrol**

Image



Patients prescribed iptacopan can help stay informed and adherent with their treatment by enrolling in **Connected - Stronger Together**

Online: [www.fabhalta-cst.co.uk](http://www.fabhalta-cst.co.uk)

Phone call: **01794 331 148**

---

## **Support programme offerings and communication channels**

Image



### **Starter kit**

A treatment starter pack that provides patients and their caregivers with information on PNH and treatment with iptacopan, along with a treatment guide, therapy diary, goal setting planner, appointment planner, contact card, and stickers for reminding patients to take their medication.

Image



### **Nurse support**

Inbound and outbound nurse calls for informational, logistical, and emotional support.

One-on-one personalised support from trained nurses can help patients be more comfortable and adherent with their treatment and disease management.<sup>2-4</sup>

Image



### **Educational resources**

Digital and print resources about PNH and iptacopan for tracking medication, symptoms, and mood over time, and for connecting with support networks. Online resources are available to patients at <https://www.fabhalta-connected-stronger-together.co.uk>.

Image



### **Emails**

Important topics related to PNH and treatment with iptacopan, including its mechanism of action, dosing, tips for establishing a medication routine, and side-effect management, plus links to additional information and resources on a website.

Emails with educational information can support patients with their treatment and provide links to download additional resources that can help with medication adherence.<sup>5</sup>

Image



### **SMS text messages**


- Daily medication reminders help patients remain adherent with their medicines each day
- Motivational texts help patients stay engaged while managing their disease and treatment

In studies, medical compliance reminders were found to improve medication regimen adherence when using an SMS-reminder intervention.<sup>5</sup>

---

Image

Prescribing information and adverse event reporting can be found at the bottom of this page.



# Helping your eligible patients prescribed FABHALTA<sup>®</sup> (iptacopan) start and stay on track with their treatment

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).

Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report) or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

FABHALTA<sup>®</sup> is indicated as a monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd. and is intended for use by UK healthcare professionals only.

Connected – Stronger Together is a patient support programme developed and funded by Novartis Pharmaceuticals UK Ltd. and is offered in partnership with IQVIA IES Ltd. It is a service for patients who have been prescribed FABHALTA<sup>®</sup> (iptacopan) for their PNH treatment.



Scan or click (if viewing digitally) the QR code to view the Prescribing Information.

## HCP brochure

PDF

[Download](#)

---

HCP, healthcare professional; PNH, paroxysmal nocturnal haemoglobinuria.

### References

1. FABHALTA® Summary of Product Characteristics
2. Lee A, et al. *J Med Internet Res* 2022;24(11):e40364.
3. Ganguli A, et al. *Patient Prefer Adherence* 2016;10:711-725.
4. Kes D & Polat U. *Int J Nurs Pract* 2022 Jun;28(3):e12995.
5. Schwebel FJ & Larimer, ME. *Internet Interventions* 2018;13:82-104.

UK | March 2025 | FA-11270182-1

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

### Source URL:

<https://www.pro.novartis.com/uk-en/medicines/haematology/fabhalta/patient-support>